- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Comparison of efficacy and safety of the treatment of entecavir and switching entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long term effects of the prospective study
Satoru Hagiwara 1 , Naoshi Nishida 1 , Kazuomi Ueshima 1 , Akihiro Yoshida 1 , Yasunori Minami 1 , Masatoshi Kudo 1
Affiliations
Affiliation
1
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
PMID: 33900663 DOI: 10.1111/hepr.13650
Abstract
Aim: Both entecavir (ETV) and tenofovir alafenamide fumarate (TAF) are widely administered for chronic hepatitis B (CHB) in Japan. Nonetheless, whether the efficacy of TAF in decreasing the hepatitis B surface antigen (HBsAg) level and its safety are superior to those of ETV remain unclear. This study aimed to report the long-term effects and safety of 96-week ETV and TAF administration in patients with CHB.
Methods: A prospective comparative observational study was conducted on the following two groups: patients with CHB who received continuous ETV administration (n = 32) and patients with CHB who were switched from ETV to TAF upon request (n = 48). HBsAg, urinary β2-microglobulin (β2MG)/creatinine (Cr), urinary N-acetyl-β-D-glucosaminidase (NAG)/Cr, serum alanine aminotransferase (ALT), estimated glomerular filtration rate (eGFR), and bone mineral density (lumbar spine and femur) at 96 weeks were compared.
Results: The two groups did not significantly differ with respect to mean age, male/female ratio, and rate of hepatitis B e antigen (HBeAg)-positive status. The mean changes in serum HBsAg level and eGFR at 96 weeks were not significantly different between the two groups. The β2MG/Cr and NAG/Cr levels at 96 weeks were similar between the two groups. Additionally, the bone mineral density of the lumbar spine and femur as well as the serum ALT did not significantly differ.
Conclusions: When compared with patients who received continuous ETV administration, those who were introduced to TAF after ETV exhibited similar effects in terms of the decrease in HBsAg level and safety. This article is protected by copyright. All rights reserved.
Keywords: N-acetyl-β-D-glucosaminidase; entecavir hydrate; hepatitis B virus; tenofovir alafenamide fumarate; tenofovir disoproxil fumarate.
This article is protected by copyright. All rights reserved. |
|